260 related articles for article (PubMed ID: 17077937)
1. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
Wu A; Wiesner S; Xiao J; Ericson K; Chen W; Hall WA; Low WC; Ohlfest JR
J Neurooncol; 2007 Jun; 83(2):121-31. PubMed ID: 17077937
[TBL] [Abstract][Full Text] [Related]
2. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity.
Castriconi R; Dondero A; Negri F; Bellora F; Nozza P; Carnemolla B; Raso A; Moretta L; Moretta A; Bottino C
Eur J Immunol; 2007 Nov; 37(11):3190-6. PubMed ID: 17918205
[TBL] [Abstract][Full Text] [Related]
3. Effect of all-trans retinoic acid on the proliferation and differentiation of brain tumor stem cells.
Niu CS; Li MW; Ni YF; Chen JM; Mei JM; Li J; Fu XM
J Exp Clin Cancer Res; 2010 Aug; 29(1):113. PubMed ID: 20716331
[TBL] [Abstract][Full Text] [Related]
4. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
5. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.
Hua W; Yao Y; Chu Y; Zhong P; Sheng X; Xiao B; Wu J; Yang B; Mao Y; Zhou L
J Neurooncol; 2011 Nov; 105(2):149-57. PubMed ID: 21479962
[TBL] [Abstract][Full Text] [Related]
6. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.
Kozlowska AK; Tseng HC; Kaur K; Topchyan P; Inagaki A; Bui VT; Kasahara N; Cacalano N; Jewett A
Cancer Immunol Immunother; 2016 Sep; 65(9):1085-97. PubMed ID: 27439500
[TBL] [Abstract][Full Text] [Related]
8. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
He J; Liu Y; Zhu T; Zhu J; Dimeco F; Vescovi AL; Heth JA; Muraszko KM; Fan X; Lubman DM
Mol Cell Proteomics; 2012 Jun; 11(6):M111.010744. PubMed ID: 22203689
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Joo KM; Kim SY; Jin X; Song SY; Kong DS; Lee JI; Jeon JW; Kim MH; Kang BG; Jung Y; Jin J; Hong SC; Park WY; Lee DS; Kim H; Nam DH
Lab Invest; 2008 Aug; 88(8):808-15. PubMed ID: 18560366
[TBL] [Abstract][Full Text] [Related]
10. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
[TBL] [Abstract][Full Text] [Related]
11. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
[TBL] [Abstract][Full Text] [Related]
12. Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens.
Kelly JJ; Stechishin O; Chojnacki A; Lun X; Sun B; Senger DL; Forsyth P; Auer RN; Dunn JF; Cairncross JG; Parney IF; Weiss S
Stem Cells; 2009 Aug; 27(8):1722-33. PubMed ID: 19544433
[TBL] [Abstract][Full Text] [Related]
13. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells.
Yao Y; Tao R; Wang X; Wang Y; Mao Y; Zhou LF
Neuro Oncol; 2009 Dec; 11(6):757-66. PubMed ID: 19264916
[TBL] [Abstract][Full Text] [Related]
14. HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells.
Wolpert F; Roth P; Lamszus K; Tabatabai G; Weller M; Eisele G
J Neuroimmunol; 2012 Sep; 250(1-2):27-34. PubMed ID: 22688424
[TBL] [Abstract][Full Text] [Related]
15. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
16. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
17. [Isolation and characterization of brain tumor stem cells in human medulloblastoma].
Li MC; Deng YW; Wu J; Chen FH; Liu JF; Fang JS
Ai Zheng; 2006 Feb; 25(2):241-6. PubMed ID: 16480595
[TBL] [Abstract][Full Text] [Related]
18. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
19. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
20. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]